JPRN-jRCT2080220568未知2 期
A Phase 2/3 Study of SYR-322 as an Add-on to a Thiazolidine
试验速览
- 阶段
- 2 期
- 入组人数
- 240
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- •Key Criteria for inclusion:
- •- The subject has been taking a stable dosage regimen of pioglitazone for at least 16 weeks prior to the initiation of the treatment period (Week 0)
- •- The subject has an HbA1c value of 6.5% or more and below 10.0% at 14 weeks after the initiation of the screening period (Week -2)
- •Key Criteria for exclusion:
- •- The subject has taken any antidiabetic medications except pioglitazone within the last 16 weeks prior to the initiation of the treatment period (Week 0)
- •- The subject with a history or symptoms of heart failure
排除标准
- 未提供
研究者
相似试验
已完成
不适用
A Phase 2/3 Study of SYR-322 as an Add-on to a ThiazolidineType 2 diabetes mellitusJPRN-UMIN000001382Takeda Pharmaceutical Company Limited240
已完成
不适用
A Phase 2/3 Study of SYR-322 as an Add-on to a MetformiType 2 diabetes mellitusJPRN-UMIN000001394Takeda Pharmaceutical Company Limited240
未知
2 期
A Phase 2/3 Study of SYR-322 as an Add-on to a MetformiType 2 diabetes mellitusJPRN-jRCT2080220606Takeda Pharmaceutical Company Limited240
未知
2 期
A Phase 2/3 Study of SYR-322 as an Add-on to a SulfonylureaType 2 diabetes mellitus.JPRN-jRCT2080220603Takeda Pharmaceutical Company Limited240
已完成
不适用
A Phase 2/3 Study of SYR-322 as an Add-on to a SulfonylureaType 2 diabetes mellitusJPRN-UMIN000001393Takeda Pharmaceutical Company Limited240